(Source: XBiotech Inc) (GLOBE NEWSWIRE via COMTEX) --- Improved clinical response seen for multiple symptoms associated with disease progression and overall survival, with notable lack of toxicity - Xilonix is the first antibody therapy to neutralize biological activity of interleukin-1 alpha (IL-1alpha), a potent anti-inflammatory signaling molecule known to promote the growth and spread of tumors - Xilonix granted accelerated review by the European Medicines Agency (EMA); an approval decision could come as early as fourth quarter 2016 AUSTIN, Texas, July 02, 2016 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ:XBIT), developer of next-generation True Human(TM) antibody therapies, today presented...
↧